Modern pharmaceutical supply chains are among the most globalised in any industry. Active pharmaceutical ingredients may be manufactured in Asia, finished drugs formulated in Europe, and distributed worldwide through complex logistics network. This system has delivered efficiency and lower costs, but it has also created structural vulnerabilities.
Escalating tensions between the United States and Iran highlight how geopolitical instability can rapidly affect industries far beyond energy and defence. For pharmaceutical companies, the implications extend from manufacturing costs to the reliability of medicine distribution.
One immediate consequence of geopolitical conflict is volatility in global energy markets.
Pharmaceutical manufacturing is highly energy intensive, particularly in the production of active pharmaceutical ingredients (APIs), biologics and chemical intermediates. When oil and natural gas prices rise, production costs increase throughout the supply chain.
Geopolitical tensions in the Middle East have already driven concerns about oil price volatility, which can translate directly into higher operating costs for drug manufacturers and contract manufacturing organisations. 1
Higher energy prices also affect petrochemical feedstocks used in solvents, plastics and packaging material essential to pharmaceutical production.
While large pharmaceutical companies may absorb some of these increases, manufacturers of low-margin generic medicines face greater financial pressure. Generic drugs often operate on narrow margins, leaving little capacity to absorb sudden increases in manufacturing or logistics costs.
Conflict in the Middle East also threatens critical shipping routes used for global trade.
The Strait of Hormuz remains one of the most important maritime corridors in the world, linking manufacturing hubs in Asia with markets in Europe and the Middle East. Disruptions to these routes have already increased freight costs and created delays across several industries, including pharmaceuticals. 2
For medicines, such delays can have disproportionate consequences. Many modern therapies - particularly biologics and vaccines, require teperature-controlled logistics and tightly coordinated distribution networks.
Even short disruptions in transport routes can create supply shortages if manufacturers are unable to replenish inventories quickly enough. 3
The broader lesson is that geopolitical risk is becoming an increasingly important consideration in pharmaceutical strategy.
Over the past two decades, the industry has prioritised efficiency by concentrating manufacturing in a limited number of global production hubs. While this model reduced costs, it also increased exposure to geopolitical and logistical shocks.
Recent crises, including the COVID-19 pandemic, the Russia-Ukraine war, and renewed instability in the Middle East, have exposed these vulnerabilities. 4
In response, pharmaceutical companies and governments are increasingly investing in supply chain resilience. Strategies include diversifying API manufacturing locations, expanding domestic production capacity, and maintaining larger strategic inventories of essential medicines.
Major pharmaceutical companies such as AstraZeneca and Pfizer have already begun reassessing manufacturing footprints and supply chain strategies following pandemic-era disruptions.
For biotechnology and pharmaceutical companies, the implication is clear: operational resilience is becoming a strategic capability rather than a logistical afterthought.
Investors and regulators are placing growing scrutiny on supply chain stability, particularly for critical medicines and biologics. Companies that rely heavily on concentrated manufacturing networks may face greater exposure to geopolitical risk. 5
In this environment, competitive advantage will not be determined solely by scientific innovation. The ability to manufacture and distribute medicines reliably during periods of global disruption may increasingly define industry leadership.